Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC) Meeting Abstract


Authors: Conlin, A. K.; Hudis, C. A.; Bach, A.; Moynahan, M.; Lake, D.; Forero-Torres, A.; Wright, G.; Hackney, M.; Clawson, A.; Seidman, A. D.
Abstract Title: Randomized phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC)
Meeting Title: 45th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 27
Issue: 15 Suppl.
Meeting Dates: 2009 May 29-Jun 2
Meeting Location: Orlando, FL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2009-05-20
Start Page: 42s
Language: English
ACCESSION: WOS:000276606601485
PROVIDER: wos
Notes: Meeting Abstract: 1006 -- Source: Wos
MSK Authors
  1. Andrew D Seidman
    243 Seidman
  2. Clifford Hudis
    839 Hudis
  3. Ariadne Bach
    56 Bach
  4. Diana E Lake
    70 Lake
  5. Alison Katherine Conlin
    18 Conlin